Unknown

Dataset Information

[<sup>18</sup>F]FDDNP PET binding predicts change in executive function in a pilot clinical trial of geriatric depression.


ABSTRACT:

Objectives

Geriatric depression often presents with memory and cognitive complaints that are associated with increased risk for Alzheimer's disease (AD). In a parent clinical trial of escitalopram combined with memantine or placebo for geriatric depression and subjective memory complaints, we found that memantine improved executive function and delayed recall performance at 12 months (NCT01902004). In this report, we used positron emission tomography (PET) to assess the relationship between in-vivo amyloid and tau brain biomarkers and clinical and cognitive treatment response.

Design

In a randomized double-blind placebo-controlled trial, we measured 2-(1-{6-[(2-[F18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile ([18F]FDDNP) binding at baseline and assessed

SUBMITTER: Krause-Sorio B 

PROVIDER: S-EPMC7375908 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature